HR Execs on the Move

Better Therapeutics

www.bettertx.com

 
Better Therapeutics ("Better") is developing first-in-class prescription digital therapeutics to deliver behavioral therapy to patients. Led by an experienced team of biotechnology executives with funding from top-tier industry investors, Better expects to go public through a merger with SPAC Mountain Crest Acquisition Corp. (NASDAQ: MCAD) during the summer of 2021. Better was founded upon the realization that nearly half a trillion dollars are spent each year treating the symptoms or effects of cardiometabolic diseases while little is being done to address the behaviors that cause them. Better has created prescription software that it believes has the opportunity to fundamentally change ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.bettertx.com
  • 548 Market Street #49404
    San Francisco, CA USA 94104
  • Phone: 415.887.2311

Executives

Name Title Contact Details
Thiago Licias de Oliveira
Chief People Officer Profile
Thiago de Oliveira
Chief People Officer Profile

Similar Companies

Family Dental

Family Dental is a Haverhill, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

United Review Services

United Review Services is a Piscataway, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Agensys

Agensys is a Santa Monica, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Genmab

Genmab is a leading international biotechnology company that aims to improve the lives of patients by creating and developing innovative antibody products. The company was founded in Copenhagen, Denmark in 1999. Genmab`s ordinary shares are publicly traded on Nasdaq Copenhagen and American Depositary Shares under its ADR Program are listed in the United States on the Nasdaq Global Select Market. Genmab is developing a pipeline of antibody therapeutics with eighteen products in clinical development, including two marketed products, DARZALEX® (daratumumab) and Arzerra® (ofatumumab), and approximately 20 in-house and partnered pre-clinical programs. Our pipeline currently includes naked antibodies, Antibody Drug Conjugates (ADCs), bispecific antibodies created from our DuoBody® technology platform, and antibodies created with our HexaBody® technology.

Alder Biopharmaceuticals

Alder uses its proprietary technologies to uniquely identify, develop, produce and market its own antibody therapeutics. The work being done at Alder today will help those who suffer from cancer, autoimmune diseases, and inflammatory diseases.